Where it all started
It all started with a drug complication that a relative of Rightangled Co-founder (Floriane) was experiencing. The medication was Plavix (Clopidogrel) and the side effects were gum bleeding and bruises. After seeing her relative survive 5 strokes, it was clear that the drug was not working and a personalised (tailored) treatment regimen was needed.
With Abdullah's knowledge about genetics and it's influence on the way people respond to drugs, him and Flo decided to make genetic information more available. Then, the concept of a new service design was born to enable the use of genetic information within the medical practice. The project later received the approval and funding from NHS England, through one of it's innovation adoption arms (the West Midlands Academic Health Science Network).
They both wanted to see a change in the way healthcare was delivered to one of their close family members, now the team at Rightangled wants to change the status quo.
Launch of Heart DNA Test
Our Heart DNA testing service was launched in mid 2017 and ever since, it has been helping private practices around the UK and abroad to remove patient-physician communication barriers, helping patients minimise their cardiac risks and reach their optimal treatment regimen faster. In the same way, Rightangled's platform has been assisting doctors to have an easy access to the complete risk profile of their patients, that is specific and evidence-based.
Fitness + Diet DNA Test Launch
In early 2019, we fully launched our second specialised genetic testing service that tapped into the fitness and wellbeing markets. The new testing service expanded Rightangled's transatlantic operations with a second branch that later opened in Austin, Texas.
COVID PCR Test Launch
In early 2020, the world went into a standstill with the COVID-19 pandemic. Rightangled was one of the very early responders to launch an at-home PCR test. The service was launched on the 21st of March 2020, and we were later listed as one of few UK government approved providers for testing international travellers arriving into the UK.
We’re working with our partner healthcare professionals on the launch of our own online pharmacy, complimenting our personalised genetic testing service with an online prescription operation. It will help and facilitate the delivery of private (and later NHS) prescriptions to people's doorsteps.
Genes and environmental factors have a complex interaction, which physical characteristics, attributes and medical conditions are a result of. To make a sensible insight and an informed treatment plan, we must first decode these causative factors.
We believe that:
Genotype + Environment = Phenotype.
To decode this simple equation, we:
A. Engage a qualified partner specialist whenever a clinical report is set to be sent out to one of our patients, in order to provide an accurate and actionable interpretation.
B. Maintain the highest level of quality and privacy in our service. Rightangled is a healthcare provider registered with the Care Quality Commission (CQC), registration number is 1-4011769845. Also, an applicant for registration at the General Pharmaceutical Council (GPhC). The superintendent and responsible pharmacist is Huda Al-Khorsan registration number 2085829.
C. Communicate information in an understandable and UI friendly manner to the general public, whilst presenting information that is appropriate for further medical advice
Abdullah SabyahChairman and CEO
A scientist-entrepreneur and the CQC registered manager of Rightangled. He is a member of the British Heart Foundation Alliance, the Clinical Pharmacogenomics Implementation Consortium in the US, and the inventor of a patent pending-technology for nucleic acid testing on a lateral flow assay.
Professor Sir John CunninghamNon-Executive Director
Lead Scientific Advisor, frontline NHS clinician at The Royal Free Hospital and Professor of Nephrology at UCL Medical School. An active researcher with over I00 papers published in peer reviewed journals. Honorary Fellow of Trinity Hall at University of Cambridge.
Dr Sibtain AnwarNon-Executive Director
Senior Lecturer and Consultant in the Department of Perioperative Medicine at the Barts Heart Centre, Europe’s largest cardiovascular institution. He also sits on the Pain Medicine Council at the Royal Society of Medicine. He completed clinical training at Imperial College London, while also pursuing his research interests as an Honorary Fellow of the Academic Cardiology Unit at The National Heart and Lung Institute.
Dr Ahmed MerghaniNon-Executive Director
Having also accomplished an intercalated BMedSci (hons) degree in Molecular Therapeutics. Dr Ahmed attained membership of the Royal College of Physicians in 2008 and went on to achieve a National training number in Cardiology at the West Midlands Deanery. Since then, he has worked as a cardiology registrar in Birmingham and Coventry. In 2012, he pursued an MD degree at St. George’s, University of London.
Mr Anas AbuyazidCorporate Governance
A seasoned banker with Environmental, Social, and Governance (“ESG”) interest. A believer in sustainability. An angel investor across multiple sectors and jurisdictions.